Antibody therapeutics represent a diverse class of large molecular weight biotherapeutics including monoclonal antibodies, antibody-drug conjugates, and fusion proteins used extensively in preclinical research for investigating disease mechanisms, therapeutic efficacy, and safety profiles. These complex biomolecules require specialized animal models and sophisticated analytical approaches to characterize their unique absorption, distribution, metabolism, and excretion properties in contract research settings.
Therapeutic Development and Clinical Significance
The global therapeutic monoclonal antibody market was valued at approximately US$115.2 billion in 2018 and is expected to generate revenue of $300 billion by 2025 . Over the past five years, antibodies have become the best-selling drugs in the pharmaceutical market, with eight of the top ten bestselling drugs worldwide being biologics in 2018 .
Current antibody drugs have increasingly fewer adverse effects due to their high specificity, making therapeutic antibodies the predominant class of new drugs developed in recent years . All currently clinically used therapeutic antibodies are immunoglobulin G (IgG) monoclonal antibodies with a molecular weight of approximately 150 kDa, composed of four polypeptide chains .
Preclinical Animal Model Requirements
Often, the only relevant species for preclinical safety assessment of monoclonal antibodies are non-human primates (NHPs), raising important scientific, ethical and economic issues . Different parameters must be considered before starting animal experiments with recombinant monoclonal antibodies, including antibody cross-reactivity, immunogenicity, pharmacokinetics, and possible interactions with the host immune system .
The very characteristics of monoclonal antibody biology that have enhanced their success as therapeutic agents, such as high target specificity and predictable metabolic stability, also provide opportunities to minimize the use of NHPs in safety testing . The most used animal models in preclinical research include rodents (mice, ferrets) and non-human primates (macaques, chimpanzees) .
Transgenic and Humanized Models
Major development efforts have yielded models such as fully human antibody mice and second-generation chimeric human antibody mice over the 30 years since the first transgenic mouse was generated in 1989 . The first human antibody generated in a transgenic mouse targeting epidermal growth factor receptor (EGFR), panitumumab, was approved by the US FDA in 2006 .
Through proprietary gene-editing technologies, companies offer thousands of off-the-shelf drug-targeted humanized models, providing ready-to-use solutions for drug efficacy, safety, and mechanistic studies . Due to species limitations, wild-type mice are typically unable to evaluate human-specific drugs effectively, necessitating genetically-modified animal models .
ADME Characterization and Pharmacokinetics
Unlike small molecule drugs which are typically widely distributed, antibodies are restricted primarily to plasma and extracellular fluid compartments . The volume of the central compartment for most monoclonal antibodies is in the range of 2-3 L, similar to plasma water, and the overall volume of distribution at steady-state is 8-20 L .
One particularly important example is the sometimes profound effect of target binding on the pharmacokinetics/pharmacodynamics of a therapeutic protein, referred to as target-mediated drug disposition (TMDD) . Charge is one of the major determinants of how a monoclonal antibody interacts with negatively charged components of the cell surface, affecting pharmacokinetic behavior in serum, interstitial space, and tissue .
Antibody-Drug Conjugates (ADCs)
Antibody-drug conjugates comprise a complex biotherapeutic modality composed of a warhead (cytotoxic drug) conjugated to a monoclonal antibody via a chemical linker, designed to selectively deliver cytotoxic payload to tumor cells . The warhead, linker and monoclonal antibody all contribute to the complexity of ADC’s overall absorption, distribution, metabolism/catabolism, and excretion properties.
While the linker, warhead, and drug/antibody ratio can affect both in vitro and in vivo stability of the ADC as a whole, typically the biodistribution and pharmacokinetics of an ADC is dominated by the properties of the targeting antibody . Understanding the pharmacokinetics, ADME properties and consequently the pharmacokinetic-pharmacodynamic properties of ADCs is critical for their successful development .
Bioanalytical Assessment Methods
Sophisticated bioanalytical assays are required for assessments of intact ADC, total antibody, released warhead and relevant metabolites . Both ligand-binding assays (LBA) and hybrid LBA-liquid chromatography coupled with tandem mass spectrometry methods have been employed to assess pharmacokinetics of ADCs .
ADME characterization services include in vitro cell-based assays, liquid chromatography-mass spectrometry and capillary electrophoresis for quantifying metabolites, confocal microscopy and fluorescence imaging for distribution tracking, and flow cytometry for cellular distribution evaluation . Current practices of ADME data generation for therapeutic proteins provide utility in discovery, development, and regulatory submissions .
Study Design and Experimental Considerations
A careful evaluation of pharmacokinetics and metabolism should play an integral and continuing role in nonclinical workup and should be initiated very early in the drug development program . These studies are of primary importance for planning and design of animal toxicity studies and for selection of appropriate animal models for estimating safe clinical doses .
Acute toxicity testing is the initial stage of toxicity research, involving testing of single or multiple exposures within a 24-hour period, requiring use of both rodent and non-rodent species . Fixed-dose methods are commonly employed for preclinical acute toxicity testing in rodents, with rats being primary research subjects .
Immunogenicity and Cross-Reactivity Assessment
Antibody humanization through recombinant DNA technology was a key step in allowing monoclonal antibodies to reach the clinic, particularly for cancer treatment . The clinical use of murine antibodies may trigger severe immunogenic responses such as human anti-mouse antibody (HAMA) responses .
Cross-reactivity studies are essential for determining appropriate animal species for preclinical evaluation. The lack of expression of target antigens in any animal tissue demonstrated by immunohistochemistry presents challenges for safety evaluation study design . Species selection requires careful consideration of target expression patterns and antibody binding characteristics.
Regulatory and Development Considerations
Preclinical studies in animals are mandatory before approval of biologics license applications for monoclonal antibodies by the U.S. Food and Drug Administration or European Agency for the Evaluation of Medicinal Products . Pre-clinical animal models show limited correlation in predicting human toxicities in phase 1 oncology clinical trials .
Along with further clarification of cancer immunobiology and advances in antibody engineering, agents targeting additional inhibitory immune checkpoints are becoming important areas of research . Companies focus on oncology, autoimmune, inflammatory, metabolic, and other diseases, with assets including monoclonal antibodies, bispecific antibodies, and bispecific ADCs .
Future Directions and Innovation
Future advances in bioanalytical techniques will need to address the rising complexity of this biotherapeutic modality as more innovative conjugation strategies, antibody scaffolds and novel classes of warheads are employed . Recently, highly mechanistic models of protein therapeutic disposition have started to be developed, particularly for monoclonal antibodies .
Nine fully human antibodies discovered from phage libraries are approved for therapy, with dozens more phage-derived antibody therapeutics in clinical trials . The continued refinement and advancement of transgenic animals provides ever more possibilities for antibody drug development by global pharmaceutical companies.
Anilocus provides comprehensive antibody research services including specialized animal model development, ADME characterization, and immunogenicity assessment. Our facility offers humanized mouse models, advanced bioanalytical capabilities, and complete preclinical pharmacology support for monoclonal antibodies, antibody-drug conjugates, and other therapeutic proteins. Our molecular biology services include target expression analysis, cross-reactivity studies, and mechanistic research to support antibody drug development programs from discovery through IND-enabling studies.
Contact us for specialized antibody research study design and protocol development.